Vapotherm Exits Public Markets Following Privatization

Vapotherm is no longer listed on major stock exchanges after its privatization concluded. With the company out of the public arena, investors in respiratory-therapy technology are turning to peers and evolving market dynamics to gauge opportunity. Who will fill the gap left by this high-velocity-therapy specialist?

• Privatization completed: Acquisition by Perceptive Advisors in September 2024.
• Transaction price: $2.18 per share.
• Focus 2026: Industry peers like Beyond Air and QuidelOrtho move into the spotlight.

As of February 2026, Vapotherm no longer trades on prominent venues such as the NYSE. With the company no longer publicly listed, active price data and trading volumes are unavailable. Former shareholders and market watchers must anchor their analyses on remaining industry leaders and medical-technology indices.

In Vapotherm?s absence, the sector?s early-2026 signals are mixed. Some players are expanding, yet profitability remains a pervasive challenge across the industry.

Beyond Air recently disclosed results for its third fiscal quarter of 2026. Revenue rose 105% year over year to $2.2 million, driven primarily by the LungFit PH system. Despite the top-line gain, the quarter recorded a net loss of $7.3 million.

QuidelOrtho also offered insight into the respiratory diagnostics market. Management described fluctuating revenue, heavily influenced by seasonal patterns tied to COVID-19 and influenza.

Should investors sell immediately? Or is it worth buying Vapotherm?

Regulatory Milestones 2026

For investors in this space, forthcoming regulatory decisions are pivotal. In Beyond Air?s case, the market awaits FDA rulings on next-generation systems, expected by the end of 2026. These decisions will materially alter the competitive landscape Vapotherm once operated within.

Hospital purchasing behavior remains a key indicator as well. Data from peers show installed-system retention rates staying above 90%, while sales cycles for new devices can extend six to nine months.

Market shares in respiratory-therapy are expected to shift in 2026. The remaining publicly traded players will need to convert the lengthy clinical purchase cycles into profitable growth and secure FDA approvals slated for the fourth quarter.

Ad

Vapotherm Stock: New Analysis - 15 February

Fresh Vapotherm information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Vapotherm analysis...